Results 91 to 100 of about 30,927 (236)

Ibrutinib Resistance in Chronic Lymphocytic Leukemia [PDF]

, 2014
Gustaaf Reurink, Gert Jan Goudswaard, Maarten H. Moen, Adam Weir, Jan A.N. Verhaar, Marco Sita, Mario Maas, Johannes L. Tol   +7 more
openalex   +1 more source

Ferroptosis in Haematological Malignancies: From Regulatory Networks to Novel Therapeutic Opportunities

Journal of Cellular and Molecular Medicine, Volume 29, Issue 17, September 2025.
ABSTRACT Haematological malignancies encompass a wide spectrum of blood cell disorders with diverse prognoses. Despite recent advances in therapy, many of these disorders remain incurable or exhibit relapse and drug resistance. Ferroptosis, an iron‐dependent form of cell death caused by lipid peroxidation, holds promise as a strategy to overcome the ...
Maryam Shayanmanesh, Seyed Esmaeil Ahmadi, Ali Amini   +2 more
wiley   +1 more source

The Impact of Tirabrutinib Monotherapy for the Treatment of Bing‐Neel Syndrome: A Multicenter Retrospective Study

American Journal of Hematology, Volume 100, Issue 10, Page 1912-1915, October 2025.
Masuho Saburi, Taro Masunari, Noriko Fukuhara, Yuichiro Inagaki, Arika Shimura, Naoto Imoto, Yuta Hasegawa, Masao Hagihara, Nobuhiko Kobayashi, Hanae Kumekawa, Hideyuki Nakazawa, Kana Miyazaki, Toshiro Kawakita, Takahiro Isshiki, Atsushi Katsube, Shin Fujisawa, Yuichi Horigome, Yusuke Koba, Fumiaki Jinnouchi, Naohiro Sekiguchi   +19 more
wiley   +1 more source

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib [PDF]

, 2014
Daphne Guinn, A. S. Ruppert, Kami J. Maddocks, Samantha Jaglowski, Anderley Gordon, Thomas S. Lin, Richard A. Larson, Guido Marcucci, E Hertlein, Jennifer A. Woyach, Amy J. Johnson, John C. Byrd   +11 more
openalex   +1 more source

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [PDF]

, 2015
Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps   +33 more
openalex   +1 more source

Ibrutinib and Rituximab in Waldenström’s Macroglobulinemia [PDF]

New England Journal of Medicine, 2018
Gian Matteo Rigolin, Francesco Cavazzini, Antonio Cuneo   +2 more
openaire   +4 more sources

Estudio de utilización de Ibrutinib en leucemia linfocítica crónica [PDF]

, 2019
La leucemia linfocítica crónica (LLC) es la leucemia más frecuente en nuestro país afectando mayoritariamente a mayores de 65 años. En los últimos años el tratamiento de la leucemia linfocítica crónica se ha visto modificado debido al ...
Beltrán Gómez, Inés
core  

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells

Brazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases. To address this challenge, optimization of DLBCL treatment regimens has focused on the strategy of combining an additional drug "X"
Fengbo Jin, Limei He, Yingying Chen, Wanlu Tian, Lixia Liu, Ling Ge, Wei Qian, Leiming Xia, Mingzhen Yang   +8 more
openaire   +3 more sources

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia [PDF]

, 2015
Sudhir Manda, Nancy M. Dunbar, Cynthia R. Marx‐Wood, Alexey V. Danilov   +3 more
openalex   +1 more source

Ibrutinib-Induced Skin Rash

Turkish Journal of Hematology, 2021
Sudhir Kirar, Ritu Gupta, Ajay Gogia, Saumyaranjan Mallick   +3 more
openaire   +2 more sources